Skip directly to page options Skip directly to A-Z link
Volume 29, Number 11—November 2023
Research Letter

Refractory Microascus Bronchopulmonary Infection Treated with Olorofim, France

Emmanuel FaureComments to Author , Olivier Brugière, Sylvie Colin de Verdiere, Fanny Vuotto, Lucie Limousin, Emilie Cardot, Camille Cordier, Pauline Coulon, Dea Garcia-Hermoso, Olivier Lortholary, and Fanny Lanternier
Author affiliations: Université de Lille, Lille, France (E. Faure); Centre Hospitalier Régional Universitaire Lille, Lille (E. Faure, F. Vuotto, C. Cordier, P. Coulon); Hôpital Foch, Suresnes, France (O. Brugière, S. Colin de Verdière, L. Limousin, E. Cardot); Institut Pasteur, Paris, France (D. Garcia-Hermoso, O. Lortholary, F. Lanternier); University Hospital Necker for Sick Children, Assistance Publique-Hôpitaux de Paris, Paris (O. Lortholary, F. Lanternier)

Main Article

Figure

Macroscopic observation of endobronchial Microascus cirrosus lesion in patient in France with refractory microascus bronchopulmonary infection before (A) and after (B) olorofim treatment. Arrows indicate the lesion.

Figure. Macroscopic observation of endobronchial Microascus cirrosus lesion in patient in France with refractory microascus bronchopulmonary infection before (A) and after (B) olorofim treatment. Arrows indicate the lesion.

Download

Main Article

Page created: October 11, 2023
Page updated: October 23, 2023
Page reviewed: October 23, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external